Skip to content
Screener

TransMedics Group, Inc. TMDX Heart Product — Revenue

Other product segments

Liver Product
$138.98M+27.7%
Lung Product
$2.82M-29.6%

Similar metrics at other companies

GigaCloud Technology logo
GCTProduct revenues — Revenue
$290.82M+28.9%
Nine Energy Service logo
NINEProduct revenues — Revenue
$45.59M+23.1%
Ondas, Inc. logo
ONDSProduct Revenue — Revenue
$38.37M+1,090%
RFL
RFLProduct Revenue — Revenue
$89K-63.4%
AMC Robotics Corporation logo
AMCIProduct Revenue — Revenue
$586.62K-68.5%
ROC
ROCProduct Revenue — Revenue
$2.32M-4.7%

Other financials

Income statement

See full
Revenue$173.9M+21.2%
Gross profit$101.2M+14.7%
Operating income$13.3M-51.5%
Net income$7.3M-71.5%
EPS (diluted)$0.20-71.4%

Balance sheet

See full
Cash & equivalents$461.7M+48.9%
Total debt$409.9M+505%
Total equity$494.0M+85.5%
Total assets$1.4B+71.3%

Cash flow

See full
Operating cash flow$24.5M+959%
CapEx$36.7M+35.6%
Free cash flow-$12.1M+59.4%

Valuation

See full
Market cap$2.78B-31.3%
Enterprise value$2.73B-26.6%
P/E16.2×-40.3×
P/S4.4×-3.2×

Profitability

See full
Gross margin59.1%-0.4pp
Operating margin14.9%+4.1pp
Net margin27%+17.0pp
FCF margin23.8%—

Returns & leverage

See full
Return on equity45.2%+22.2pp
Debt / equity0.8×+0.6×
Current ratio6.7×-2.4×

Where this comes from

Reported directly by TransMedics Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: TransMedics Group, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-206453
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Revenue:
Net product revenue$107,972$88,234
Service revenue65,96155,303
Total revenue173,933143,537
Cost of revenue:
Cost of net product revenue24,30816,312
Cost of service revenue48,46438,997
Total cost of revenue72,77255,309

Item 1. Financial Statements (Unaudited)

FAQ

What is TransMedics Group, Inc.'s heart product — revenue?
TransMedics Group, Inc. (TMDX) reported heart product — revenue of $30.87M in Q1 2026.
How has TransMedics Group, Inc.'s heart product — revenue changed year-over-year?
TransMedics Group, Inc.'s heart product — revenue increased by 3.5% year-over-year, from $29.82M to $30.87M.
What is the long-term trend for TransMedics Group, Inc.'s heart product — revenue?
Over 4 years (2021 to 2025), TransMedics Group, Inc.'s heart product — revenue has grown at a 63.4% compound annual growth rate (CAGR), from $17.68M to $126.01M.
What does heart product — revenue mean?
This metric represents the total gross sales generated from the sale and service of heart-related organ perfusion and monitoring technologies. It reflects the market adoption and commercial performance of the company's specialized medical devices designed to preserve donor hearts outside the body. Growth in this revenue stream indicates successful penetration into the organ transplant clinical market and the expansion of the installed base for heart-specific medical solutions.

Ask your AI about TransMedics Group, Inc.'s heart product — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude